Medically Reviewed by: Dr. Dipak Ladda, M.D.
Expertise: Consultant Pathologist
Last Updated: July 27, 2026
Medical Analysis
Comprehensive Medical Analysis of Factor V, Coagulation Pathways, and Clinical Biomarkers
Introduction – Factor V
Factor V is a cofactor glycoprotein required in both the coagulation and anticoagulation pathways [3, 6]. It is synthesized in the liver and released into the blood in an inactive form [9]. The fate of Factor V depends on modification by either activated Factor X or APC [3, 6]. Activated FV (FVa) is a cofactor in the conversion of prothrombin to thrombin, whereas zymogen Factor V acts as a cofactor with protein S for activated protein C-mediated inhibition of FVIIIa [3, 6]. Factor V deficiency is a very rare bleeding disorder, known as Owren disease or parahemophilia, and can be seen in either a congenital or an acquired form [4, 10].
Physiological Role of Factor V and Coagulation Cascade Mechanics
Factor V plays a dual role in the regulation of the coagulation cascade [3, 6]. Defects in Factor V can either cause thrombosis or increased bleeding [3, 4, 5, 10]. Normal functioning Factor V contributes to appropriate hemostasis, though overall homeostatic function relies on many different components in the coagulation cascade [1, 2]. A complex of thrombin with the endothelial cell receptor thrombomodulin activates protein C (APC) [3, 6]. This activation cascades from Factor V to Factor V-A, prothrombin to thrombin, and fibrinogen to fibrin, alongside the transition from inactivated platelets to activated platelets with platelet plus, culminating in clot formation [1, 2, 8].
Clinical Indications for Factor V Testing
Haematemesis [7]
Ecchymosis [7]
Prolonged bleeding after surgery or trauma [7]
Melena [7]
Easy Bruising [7]
APC Resistance Profile with reflex to Factor V Leiden [5, 7]
Haemarthrosis [7]
Petechiae [7]
Menorrhagia [7]
Haematuria [7]
Epistaxis [7]
Haemoptysis [7]
Patient Instructions Prior to Testing
Avoid anticoagulants (Warfarin) at least 2 weeks prior to testing [7].
Avoid direct Xa, heparin, and thrombin inhibitors at least 3 days prior to testing [7].
Do not draw blood from a heparinized catheter [7].
Specimen Collection and Handling Protocols
For citrated plasma collection, collect 9 parts blood to that of 3.8% Trisodium citrate solution present in the vial [7]. Separate plasma immediately, freeze plasma rapidly, and transport the specimen to the laboratory on dry ice in a suitable container [7]. As far as possible, carry out testing within four hours from the time of specimen collection [7]. For immunohistochemistry, formalin-fixed tissue embedded in a paraffin block is used for this test [7].
Assay Methods and Detection Techniques
Assay methods include the Activated Protein C Resistance (APCR) Assay, Polymerase Chain Reaction (PCR), Restriction Fragment Length Polymorphism (RFLP) Analysis, Real-Time PCR (qPCR), DNA Sequencing, Allele-Specific Oligonucleotide (ASO) Hybridization, Enzyme-Linked Immunosorbent Assay (ELISA) for mutation products, Ligase Chain Reaction (LCR), Multiplex PCR, and High-Resolution Melting (HRM) Analysis [5, 7].
Immunohistochemistry (IHC) and Antigen Staining Patterns
Immunohistochemistry (IHC) staining was used to detect FV antigen in formalin-fixed paraffin-embedded (FFPE) sections of breast cancer tissue (with adjacent normal tissue), and it is also carried out on placental tissue, amniotic fluid, and other specimens [7]. FV positivity was defined as moderate to strong coarse/granular cytoplasmic staining, with the endothelium acting as a positive internal control [7].
Normal Reference Ranges (% Activity)
| Age | Reference Interval | Age | Reference Interval |
| 1-4 days | 36-108% [7] | 7-9 years | 69-132% [7] |
| 5-29 days | 45-145% [7] | 10-11 years | 66-136% [7] |
| 30-89 days | 62-134% [7] | 12-13 years | 66-135% [7] |
| 90-179 days | 48-132% [7] | 14-15 years | 61-129% [7] |
| 180-364 days | 55-127% [7] | 16-17 years | 65-131% [7] |
| 1-5 years | 79-127% [7] | 18 years and older | 62-140% [7] |
| 6 years | 63-116% [7] |
Prognostic Significance and Deficiency Classification
High plasma levels of Factor V increase prothrombinase activity and in turn increase the risk of thrombosis [1, 8, 11]. Deficiency is classified into three categories depending upon Factor V activity [4, 10].
| Deficiency | % Activity to that of normal |
| Mild | > 10% [4, 10] |
| Moderate | 1-10% [4, 10] |
| Severe | < 1.0% [4, 10] |
Differentiation Between Congenital and Acquired Disorders
To differentiate between congenital and acquired disorders, control plasma is added to the patient’s plasma [7, 9]. If corrected, it indicates an acquired deficiency [7, 9]. If activity remains less than normal and is not corrected, it points to a congenital deficiency where inhibition factors are present [4, 7, 10].
Factor V: IHC Results Interpretation
| Condition | Factor V IHC Result | Interpretation |
| Normal tissue | Positive [7] | Normal expression in endothelial cells, megakaryocytes, and platelets [7] |
| Venous thromboembolism (VTE) | Borderline to Positive [11] | Increased expression may indicate enhanced procoagulant activity and thrombosis risk [11] |
| Factor V Leiden mutation carriers | Borderline [5] | Altered expression due to mutation affecting cofactor function; may show variable staining [5] |
| Coagulation factor V deficiency | Negative [4, 10] | Reduced or absent staining correlates with decreased protein levels and bleeding tendency [4, 10] |
| Cancer (e.g., breast tumor) | Positive [7] | Overexpression linked with tumor immune infiltration and potentially better prognosis [7] |
| Autoimmune conditions | Borderline [7] | Variable positivity due to antibodies or altered expression in inflammatory states [7] |
Diagnostic Utility Across Clinical Scenarios
| Clinical Scenario | Utility of Positive FVL Result | Management Implication |
| Unprovoked VTE | Confirms genetic risk for initial clot [5, 11] | Supports longer anticoagulation (secondary prevention) [5, 11] |
| Recurrent VTE | Identifies underlying cause of recurrence [5, 11] | Supports indefinite anticoagulation (high recurrence risk) [5, 11] |
| Women Seeking Estrogen (e.g., contraceptives, HRT) | Identifies those with a significantly higher VTE risk from estrogen [5, 11] | Strongly contraindicates estrogen use (must use alternatives) [5, 11] |
| First-Degree Relatives | Screens asymptomatic high-risk individuals [5, 10] | Advises on thrombosis prophylaxis during high-risk times (surgery, pregnancy) [5, 10, 11] |
| Recurrent Pregnancy Loss | May be tested as part of a thrombophilia panel (controversial evidence) [5] | May influence pregnancy management (e.g., LMWH use), but not standard [5] |
Comprehensive Summary of Clinical Significance
| Clinical Aspect | Significance Summary |
| Thrombotic Risk | 4- to 8-fold increased VTE risk [5] |
| Heredity | Inherited autosomal dominant pattern [5, 10] |
| Severity | Homozygous is much higher risk (up to 80x) than heterozygous [5] |
| Risk Multiplier | Risk is additive with other thrombophilias (e.g., Factor II) [5, 11] |
| Hormone Risk | Factor V Leiden (FVL) strongly contraindicates estrogen (e.g., most oral contraceptives) [5, 11] |
| Pregnancy Risk | Associated with slightly increased VTE risk in pregnancy [5, 11] |
For Non-Medicos
Understanding Factor V and Blood Clotting
Factor V is a liver-made protein that helps control blood clotting and prevents excessive bleeding or dangerous clots [3, 9]. Deficiencies or genetic mutations can significantly alter thrombosis and hemorrhage risks [4, 5, 10, 11].
Preparing for Your Blood Test
Stop taking Warfarin two weeks prior, avoid direct Xa, heparin, and thrombin inhibitors for three days, and never draw samples from a heparinized catheter [7].
Interpreting Test Results and Health Risks
Test results evaluate clotting percentages across age groups [7]. Conditions like Factor V Leiden increase blood clot risks, especially when combined with hormone treatments like estrogen [5, 11].
References:
Mann, K. G. (1999). Biochemistry and physiology of blood coagulation. Thrombosis and Haemostasis, 82(2), 165–174.
Furie, B., & Furie, B. C. (2005). Thrombus formation in vivo. Journal of Clinical Investigation, 115(12), 3355–3362.
Dahlbäck, B. (2003). Blood coagulation. The Lancet, 361(9369), 1627–1632.
Mannucci, P. M., & Duga, S. (2008). Phenotypes and genotypes of rare bleeding disorders. Haemophilia, 14(3), 41–49.
Bertina, R. M., Koeleman, B. P., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994). Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369(6475), 64–67.
Esmon, C. T. (2000). Regulation of blood coagulation. Biochimica et Biophysica Acta (BBA) – Protein Structure and Molecular Enzymology, 1477(1-2), 349–360.
Triplett, D. A. (2000). Coagulation assays. American Journal of Clinical Pathology, 114(Suppl 1), S98–S111.
Hoffman, M., & Monroe, D. M. (2001). A cell-based model of hemostasis. Thrombosis and Haemostasis, 85(6), 958–965.
Mammen, E. F. (1998). Coagulation abnormalities in liver disease. The Gastroenterologist, 6(1), 16–23.
Seligsohn, U., & Zivelin, A. (2007). The genetics of hereditary blood clotting disorders. Thrombosis and Haemostasis, 98(1), 101–109.
Lane, D. A., Grant, P. J., & Gray, S. (1994). Genetic risk factors for venous thrombosis. Blood Coagulation & Fibrinolysis, 5(5), 785–799.
FAQ’s:
- What is Factor V?
A liver-produced cofactor glycoprotein required in both coagulation and anticoagulation pathways. - What is its role?
Activated FV assists prothrombin conversion, while zymogen aids APC-mediated FVIIIa inhibition. - What causes Factor V deficiency?
It is a very rare bleeding disorder, known as Owren disease, occurring in congenital or acquired forms. - What are testing indications?
Indications include severe bruising, menorrhagia, GI bleeding, and APC resistance profiles. - What medications must be avoided?
Avoid Warfarin for two weeks, direct Xa, heparin, and thrombin inhibitors for three days. - How is plasma collected?
Collect nine parts blood to one part 3.8% trisodium citrate, separate, and freeze rapidly. - What assays detect mutations?
Methods include APCR assays, PCR, RFLP analysis, DNA sequencing, and ELISA for mutations. - How is deficiency classified?
Deficiency is categorized into mild, moderate, and severe based on activity percentages. - How to differentiate disorder types?
Adding control plasma corrects acquired deficiencies but fails to correct congenital ones. - What risks does Factor V Leiden carry?
It increases venous thromboembolism risk, strongly contraindicating estrogen use.
